Soleus Private Equity Fund III L.P. 13D and 13G filings for Inhibikase Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-10-28 4:00 pm Purchase |
2024-10-21 | 13G | Inhibikase Therapeutics, Inc. IKT |
Soleus Private Equity Fund III L.P. | 7,228,908 9.990% |
7,228,908 (New Position) |
Filing |